The DOI matches its Crossref record; 47 of the 53 references it cites were found in a registry or an index.
Analysis of TP53 Mutation Status in Human Cancer Cell Lines: A Reassessment
Open accessAbstract
Tumor-derived cell lines play an important role in the investigation of tumor biology and genetics. Across a wide array of studies, they have been tools of choice for the discovery of important genes involved in cancer and for the analysis of the cellular pathways that are impaired by diverse oncogenic events. They are also invaluable for screening novel anticancer drugs. The TP53 protein is a major component of multiple pathways that regulate cellular response to various types of stress. Therefore, TP53 status affects the phenotype of tumor cell lines profoundly and must be carefully ascertained for any experimental project. In the present review, we use the 2014 release of the UMD TP53 database to show that TP53 status is still controversial for numerous cell lines, including some widely used lines from the NCI-60 panel. Our analysis clearly confirms that, despite numerous warnings, the misidentification of cell lines is still present as a silent and neglected issue, and that extreme care must be taken when determining the status of p53, because errors may lead to disastrous experimental interpretations. A novel compendium gathering the TP53 status of 2,500 cell lines has been made available (http://p53.fr). A stand-alone application can be used to browse the database and extract pertinent information on cell lines and associated TP53 mutations. It will be updated regularly to minimize any scientific issues associated with the use of misidentified cell lines (http://p53.fr).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, p53 is mutated or altered in multiple immortalized cell lines 62,63 , resulting in altered DDR.”
From AAV vectors trigger DNA damage response-dependent pro-inflammatory signalling in human iPSC-derived CNS models and mouse brain (2025) · cites this paper as [62]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
PLAQUE FORMATION AND ISOLATION OF PURE LINES WITH POLIOMYELITIS VIRUSES
Dulbecco, R., & Vogt, M. (1954) · The Journal of Experimental Medicine · doi:10.1084/jem.99.2.167 · Cited by 3,837
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppé, J., Tong, F. K., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,224
Self-citationThe NCI60 human tumour cell line anticancer drug screen
Shoemaker, R. H. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1951 · Cited by 2,673
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279
A small-cell lung cancer genome with complex signatures of tobacco exposure
Pleasance, E., Stephens, P. J., O’Meara, S., McBride, D. J., Meynert, A. M., Jones, D., Lin, M., Beare, D. M., Lau, K. W., Greenman, C., et al. (2009) · Nature · doi:10.1038/nature08629 · Cited by 1,076
Self-citationp53 mutations in colorectal cancer.
Rodrigues, N. R., Rowan, A., Smith, M. E., Kerr, I. B., Bodmer, W. F., Gannon, J., & Lane, D. P. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.19.7555 · Cited by 1,002
(1952) · Cancer Research · Cited by 987
Flagged first, then by citations
6 of the 53 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–227 of 227
Data from MicroRNA-324-5p–CUEDC2 Axis Mediates Gain-of-Function Mutant p53-Driven Cancer Stemness
Ghatak, D., Datta, A., Roychowdhury, T., Chattopadhyay, S., & Roychoudhury, S. (2023) · doi:10.1158/1541-7786.c.6545358.v1
PPM1D/Wip1 is amplified, overexpressed, and mutated in human Non-Hodgkin LymphomasPreprint
Pi̇levneli̇, H., Döger, F. K., Karagenç, L., Kozacı, L. D., & Eren, M. K. (2024) · Research Square · doi:10.21203/rs.3.rs-4021011/v1
PPM1D/Wip1 is amplified, overexpressed, and mutated in human non-Hodgkin's lymphomas
Pi̇levneli̇, H., Döger, F. K., Karagenç, L., Kozacı, L. D., & Eren, M. K. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-10029-2
Differences in the role of Gper1 in colorectal cancer progression depending on sex
Herichová, I., Reis, R. D. F., & Vanátová, D. (2025) · Oncology Letters · doi:10.3892/ol.2025.15051
Alhammer, A. H., Mudhafar, S. A., & Abdulfattah, S. Y. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178195
Carey, M., O’Donovan, T. R., Coveney, C. M., & McKenna, S. (2025) · Experimental Cell Research · doi:10.1016/j.yexcr.2025.114768
Proximity map for p53 unveils a strong link with PML Nuclear Bodies in HEK293 cellsPreprint
Bruycker, E. D., Vandemoortele, G., Sutter, D. D., Moschonas, G. D., & Eyckerman, S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.22.683840
Zheng, J.-J., He, Y., Liu, Y., Li, F., Cui, Z., Du, X.-M., Wang, C.-P., & Wu, Y.-M. (2020) · Figshare · doi:10.6084/m9.figshare.12398777
Ragu, M. E., Lim, J., Ng, P.-S., Yip, C.-H., Rajadurai, P., Teo, S.-H., & Pan, J.-W. (2024) · Figshare · doi:10.6084/m9.figshare.26585124
Ragu, M. E., Lim, J., Ng, P.-S., Yip, C.-H., Rajadurai, P., Teo, S.-H., & Pan, J.-W. (2024) · Figshare · doi:10.6084/m9.figshare.26585127
Zheng, J.-J., He, Y., Liu, Y., Li, F., Cui, Z., Du, X.-M., Wang, C.-P., & Wu, Y.-M. (2020) · Figshare · doi:10.6084/m9.figshare.12398789
Ragu, M. E., Lim, J., Ng, P.-S., Yip, C.-H., Rajadurai, P., Teo, S.-H., & Pan, J.-W. (2024) · Figshare · doi:10.6084/m9.figshare.26585121
Zheng, J.-J., He, Y., Liu, Y., Li, F., Cui, Z., Du, X.-M., Wang, C.-P., & Wu, Y.-M. (2020) · Figshare · doi:10.6084/m9.figshare.12398798
Zheng, J.-J., He, Y., Liu, Y., Li, F., Cui, Z., Du, X.-M., Wang, C.-P., & Wu, Y.-M. (2020) · Figshare · doi:10.6084/m9.figshare.12398771
Zheng, J.-J., He, Y., Liu, Y., Li, F., Cui, Z., Du, X.-M., Wang, C.-P., & Wu, Y.-M. (2020) · Figshare · doi:10.6084/m9.figshare.12398795
Wen, Y.-C., Lin, Y.-W., Ho, K.-H., Yang, Y.-C., Lai, F.-R., Chu, C.-Y., Chen, J.-Q., Lee, W.-J., & Chien, M.-H. (2024) · Figshare · doi:10.6084/m9.figshare.27124109
Zheng, J.-J., He, Y., Liu, Y., Li, F., Cui, Z., Du, X.-M., Wang, C.-P., & Wu, Y.-M. (2020) · Figshare · doi:10.6084/m9.figshare.12398783
Wen, Y.-C., Lin, Y.-W., Ho, K.-H., Yang, Y.-C., Lai, F.-R., Chu, C.-Y., Chen, J.-Q., Lee, W.-J., & Chien, M.-H. (2024) · Figshare · doi:10.6084/m9.figshare.27124106
Zheng, J.-J., He, Y., Liu, Y., Li, F., Cui, Z., Du, X.-M., Wang, C.-P., & Wu, Y.-M. (2020) · Figshare · doi:10.6084/m9.figshare.12398774
Mechanism of action of a new organometallic compound inhibitor of topoisomerase I in adenocarcinomas
Molinaro, C. (2023) · theses.fr (ABES) · doi:10.70675/98b43d98zd02bz42a9z89ebz27012480adda
Shayeghan, M., Shahriari, F., Afroughi, F., Forouzesh, F., Niakan, M. H., & Javidi, M. A. (2026) · The Breast Journal · doi:10.1155/tbj/9572421
Nguyen, B. D., & Kolluri, S. K. (2026) · APOPTOSIS · doi:10.1007/s10495-026-02410-2
Cataldi, V., Tailor, D., Montaño, A. R., Rizvi, S. Z. H., Chakraborty, S., Saldivar, J. C., Malhotra, S. V., Wang, L. G., Gibbs, S. L., & Alani, A. W. G. (2026) · Cancers · doi:10.3390/cancers18162684
Ibrahim, R. A., Wan, H., Kumar, R., Teh, M., Kang, A., Bailey, E., Cottom, H., Biddle, A., Sequeira, I., & Fortune, F. (2026) · The Journal of Pathology · doi:10.1002/path.70123
Metadata
- Authors
- Leroy, B., Girard, L., Hollestelle, A., Minna, J. D., Gazdar, A. F., & Soussi, T.
- Affiliations
- Université Pierre-et-Marie-Curie (FR)
- The University of Texas Southwestern Medical Center (US)
- Erasmus MC Cancer Institute (NL)
- Karolinska Institutet (SE)
- Corresponding author
- Soussi, Thierry
- Venue
- Human Mutation
- Publisher
- Wiley
- Published
- 2014-05-06
- Volume
- 35
- Issue
- 6
- Pages
- 756-765
- ISSN
- 1059-7794 (ISSN-L)
- PMC
- PMC4451114
- OpenAlex
- W2030503662
- Cited by
- 224
- References
- 53
- Citations by year
- 2026: 6 · 2025: 20 · 2024: 16 · 2023: 20 · 2022: 29 · 2021: 25 · 2020: 40 · 2019: 20 · 2018: 18 · 2017: 15 · 2016: 3 · 2015: 7 · 2014: 4
- FWCI
- 1.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Human Mutation (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Funders
- National Cancer Institute (P50CA070907)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Keywords
- TP53 mutation status, cancer cell lines, cell line misidentification, p53, anticancer drug screening
- MeSH terms
- Humans, Mutation, Neoplasms, Software, Tumor Suppressor Protein p53, Internet, Databases, Genetic, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
